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Abstract
Introduction: This study evaluated leprosy rates in Rio Grande do Sul, an area with a historically low prevalence. However, 
recent studies are lacking. Methods: Data extracted from a National Database were analyzed for clinical features and compared 
to 1980s data. Tendency was assessed via stationarity analysis. Results: Between 1990 and 2011, 4,770 cases were reported 
(0.21/10,000 inhabitants; 95% CI = 0.19-0.24). Detection was slightly higher among males, 1.9% cases were among children 
and most multibacillary (74.7%) at diagnosis. Conclusions: Leprosy is controlled in RS, but most cases are multibacillary. Early 
identification is important to avoid disabilities due to late diagnosis.
Keywords: Leprosy. Epidemiological survey. Rio Grande do Sul.
Leprosy is a chronic infectious disease caused by 
Mycobacterium leprae that primarily affects Schwann cells 
and the skin. The upper airways are the main entry point and 
route of elimination of the bacillus1. Disease characteristics 
are dependent on host immune response, generating a wide 
clinical and histopathologic spectrum from a pole of resistance 
(tuberculoid pole) to a pole of susceptibility (lepromatous 
pole). Besides these opposing poles, there are two additional 
clinical forms: indeterminate and borderline, whose features 
may vary from one pole to another in the disease evolution1,2. 
The World Health Organization (WHO) also classifies leprosy 
operationally, for chemotherapeutic purposes as either 
paucibacillary (PB) (cases with up to five skin lesions and/or 
one impaired nerve) and multibacillary (MB) (cases with more 
than five skin lesions and/or one or more affected nerves). The 
PB and MB classifications correspond approximately to the 
tuberculoid and lepromatous poles, respectively1. 
When not diagnosed and treated early, leprosy and its 
associated sequelae can cause disabilities and physical 
deformities, leading to occupational and psychosocial 
problems3. Leprosy is curable if diagnosed early which can 
prevent the development of long-term sequelae and reduce rates 
of transmission through disruption of the transmission chain1.
Leprosy is a major public health problem in Brazil1 and in 
several countries globally. At the end of 2000, leprosy rates 
were still endemic in 15 countries (prevalence above 1.0/10,000 
inhabitants). According to WHO, in 2009, Brazil remained one 
of six countries in the world with the highest prevalence of 
leprosy4,5. In 1991, the WHO elimination target was defined as 
a prevalence less than 1 case per 10,000 inhabitants. The same 
year, multidrug therapy (MDT) with rifampicin, clofazimine, 
and dapsone was implemented as the main strategy to combat 
and eliminate leprosy, in addition to early detection6. 
Around 80% of new cases are diagnosed in countries located 
in the intertropical area7. In Brazil, more than 30,000 new cases 
of leprosy are diagnosed annually. In 2014, the prevalence of 
leprosy in Brazil was 1.27/10,000 inhabitants. However, the 
Rio Grande do Sul (RS),Brazil’s most Southern state (at the 
border with Uruguay and Argentina), is considered an area 
where the disease is eliminated, having the country’s lowest 
prevalence at 0.16/10,000 inhabitants8. Thus, few recent studies 
have examined the epidemiology of leprosy in RS, making it 
difficult to evaluate disease trends for the last twenty years. 
Therefore, this study aimed to compare leprosy data from RS 
in the 1980s to that observed in the period from 1990 to 2011 
and to assess the current situation of leprosy in RS.
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Year of diagnosis Unknown 0-14 yo Percentage ≥15 yo Percentage Total Male Female Ratio
1982-1986 0 23 2.2 999 97,8 1,022
508 524 0.97
1987-1988 0 18 5.4 314 94.6 332
185 151 1.23
Total 1982-1988 0 41 3.0 1,313 96.9 1,354 693 675 1.03
1990 0 6 3.5 167 96.5 173 105 68 1.54
1991 1 5 2.8 171 97.2 176 92 84 1.10
1992 4 7 3.2 211 96.8 218 109 109 1.00
1993 4 3 1.7 174 98.3 177 96 81 1.19
1994 2 6 3.1 185 96.9 191 116 75 1.55
1995 5 2 1.1 189 98.9 191 97 94 1.03
1996 6 3 1.4 217 98.6 220 120 100 1.20
1997 5 6 2.7 212 97.2 218 109 109 1.00
1998 2 4 1.9 198 98.0 202 119 83 1.43
1999 0 0 0 216 100 216 121 95 1.27
2000 0 5 2.2 225 97.8 230 112 118 0.95
2001 0 5 2.2 219 97.8 224 121 103 1.17
2002 0 6 2.1 280 97.9 286 143 143 1.00
2003 0 5 1.8 265 98.1 270 130 140 0.93
2004 0 10 3.8 255 96.2 265 120 145 0.83
2005 0 2 0.7 263 99.2 265 134 131 1.02
2006 1 0 0 251 99.6 252 126 126 1.00
2007 0 4 1.8 222 98.2 226 111 115 0.97
2008 0 2 0.9 215 99.1 217 122 95 1.28
2009 0 2 1.0 191 98.9 193 94 99 0.95
2010 0 5 2.9 165 97.1 170 93 77 1.21
2011 0 2 1.0 188 98.9 190 103 87 1.18
Total 1990 - 2011 30 90 1.9 4,679 98.1 4,770 2,493 2,277 1.09
TABLE 1
New cases of leprosy by sex and age group for the periods 1982-1988 and 1990-2011.
This was an ecological study, in which leprosy data in 
RS were analyzed for the period 1990-2011 by evaluating 
data included in the Notifiable Diseases Information System 
[Sistema de Informação de Agravos de Notificação (SINAN) 
database5. The SINAN is the national registration system for 
notifications and investigations of leprosy cases. Data were 
collected for cases with notification and residence in RS across 
the following variables: new cases by sex and age, WHO 
operational classification and clinical form. 
Detection rates overall and for children younger than 15 
years of age were extracted from population data collected by the 
2000 Census and population estimates of the Brazilian Institute 
of Geography and Statistics [Instituto Brasileiro de Geografia e 
Estatística (IBGE)]9, available on the website of the Department 
of Informatics of the Unified Health System [Departamento 
de Informática do Sistema Único de Saúde (DATASUS)]8. 
Descriptive data analysis was performed through calculation 
of simple absolute and percentage frequencies for categorical 
variables. Results were compared with data published by 
Cestari et al10, referring to 1980s data and were presented as 
rates per 10,000 inhabitants using 95% confidence intervals 
(95% CI). To test the stationarity of graphically presented 
data, the Dickey-Fuller test was used through the R Project 
Package - t series.
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T: tuberculoid form; L+B: lepromatous + borderline forms; PB: paucibacillary; MB: multibacillary; %: percentage.
Year of diagnosis T % L+B % Unknown % PB % MB % Total
1982-1986 236 25.6 687 74.4 - - - - - - -
1987-1988 35 12.4 247 87.6 - - - - - - -
Total 1982-1988 271 22.5 934 77.5 - - - - - - -
1990 27 17.9 124 82.1 0 0.0 49 28.3 124 71.7 173
1991 31 19.5 128 80.5 0 0.0 48 27.3 128 72.7 176
1992 35 17.3 167 82.7 0 0.0 51 23.4 167 76.6 218
1993 38 24.2 119 75.8 0 0.0 59 33.3 118 66.7 177
1994 41 23.3 135 76.7 0 0.0 56 29.3 135 70.7 191
1995 40 22.5 138 77.5 0 0.0 53 27.7 138 72.2 191
1996 44 21.1 164 78.8 0 0.0 56 25.4 164 74.5 220
1997 33 16.4 168 83.6 0 0.0 50 22.9 168 77.1 218
1998 39 20.2 154 79.8 0 0.0 48 23.8 154 76.2 202
1999 48 24.0 152 76.0 0 0.0 62 28.7 154 71.3 216
2000 36 17.9 165 82.1 2 0.9 61 26.5 167 72.6 230
2001 38 21.6 138 78.4 3 1.3 78 34.8 143 63.8 224
2002 33 15.4 181 84.6 7 2.4 65 22.7 214 74.8 286
2003 41 20.2 162 79.8 5 1.8 62 22.9 203 75.2 270
2004 39 17.6 182 82.3 3 1.1 61 23.0 201 75.8 265
2005 37 16.5 187 83.5 1 0.4 50 18.9 214 80.7 265
2006 42 80.1 167 79.9 2 0.8 55 21.8 195 77.4 252
2007 17 11.8 127 88.2 1 0.4 44 19.5 181 80.1 226
2008 36 22.1 127 77.9 1 0.5 53 24.4 163 75.1 217
2009 32 20.2 126 79.7 0 0.0 44 22.8 149 77.2 193
2010 32 23.9 102 76.1 0 0.0 40 23.5 130 76.5 170
2011 27 19.7 110 80.3 1 0.5 34 17.9 155 81.6 190
Total 1990-2011 786 19.6 3,223 80.4 26 0.5 1,179 24.7 3,565 74.7 4,770
TABLE 2
New cases of leprosy by clinical form for the periods 1982-1988 and 1990-2011, and according to the WHO classification for the period 1990-2011.
The results of this study showed that, during the period 
of 1990-2011, 4,770 cases of leprosy were registered in RS. 
The new-case detection rate identified was considered low 
by patterns normally observed in Brazil [(0.21 cases/year per 
10,000 inhabitants (95%CI = 0.19-0.24)]. This was similar to 
the 1980s rate of, 0.25 cases/year per 10,000 inhabitants (95% 
CI = 0.20-0.27). 
This study identified a decrease in detection of new cases 
with the stationarity analysis showing no significant result (p = 
0.701). However, parameters were softened to reduce variability 
among the evaluated years. Therefore, the data obtained shows 
a declining trend in the detection of new cases over the 30 years 
observed (Figure 1A). 
The rate of new cases from the 1990s was slightly higher 
among males with a mean male/female (M/F) ratio of 1.09, 
reaching 1.5 in some years within the period. This pattern was 
not observed between 1975 and 1988 within which a M/F mean 
ratio of 1.00 was observed (Table 1). The new-case detection 
rate in children younger than 15 years of age decreased during 
the 1990-2011 period compared to the 1980s (1.9% vs 3.0%) 
(Table 1). 
Throughout both periods, there was a higher average 
detection of lepromatous and borderline leprosy forms, from 
77.5%/year in the 1980s to 80.4%/year during the period 
1990-2011 (Table 2). Moreover, when grouped according to 
the WHO operational classification (Table 2), there was a 
74.7% rate of MB detection during the period 1990-2011. This 
rate coincides with the classification according to clinical form 
if the MB classification is considered as the lepromatous and 
borderline leprosy forms. It was also observed - by stationarity 
analysis of the incidence percentage of MB cases within the last 
22 years - that an upward trend in the proportion of these cases 
was identified in this study, because there was no significant 
stationarity (p = 0.342) (Figure 1B). No pattern was identified 
regarding percentage of diagnoses according to the disability 
grade 2. (Figure 1C).
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According to Ministry of Health parameters, a geographical 
region can be classified as: (A) hyperendemic - 4.00 cases 
or more/10,000 inhabitants; (B) very high - from 2.00 to 
3.99 cases/10,000 inhabitants; (C) high - from 1.00 to 1.99 
cases/10,000 inhabitants; (D) intermediate - 0.20 to 0.99 
cases/10,000 inhabitants; or (E) low - less than 0.2 cases/10,000 
inhabitants11. As shown in Figure 1, RS has remained classified 
as low/intermediate endemicity during the past 30 years. The 
recent slight decrease in the incidence of leprosy in RS compared 
to the 1980s is likely due to the introduction of multidrug therapy 
(rifampicin + dapsone + clofazimine) in 1991, which reduced 
disease transmission through interruption of the transmission 
chain upon initiation of treatment. Detection rates serve as 
indicators of leprosy transmissibility in Brazil and, according to 
WHO, leprosy detection has showed no decline in recent years1. 
Despite this, regional indicators of RS have always remained 
below the national average.
Leprosy is a chronic, low mortality, and late mortality disease 
that often goes undiagnosed, especially in low endemicity areas. 
Additionally, stigma still surrounds a diagnosis of leprosy 
causing patients to avoid seeking health services for confirmed 
diagnosis and treatment. Owing to this, estimating the actual 
magnitude of leprosy is very difficult, given that a low number 
of new cases and low rate of registration could either mean 
that the disease is not significant in the area, or that there are 
operational problems (such as a high number of unreported 
cases)12,13. Therefore, to indirectly assess the real magnitude of 
the disease, WHO recommends the use of the proportion of MB 
patients and the proportion of new cases in children younger 
than 15 years of age as valid epidemiological indicators 12. New 
cases of leprosy in children younger than 15 years of age are 
related to the bacillus transmission chain within the community 
and the existence of an active transmission focus14. Currently, 
detection rate among the 0-14-year age group is considered, by 
the Brazilian Ministry of Health, the primary disease control 
indicator3. However, this indicator is most useful for high 
prevalence areas with high rates of diagnosis in children and 
adolescents. In low prevalence areas, such as RS, the rate of 
newly affected children younger than 15 years of age is very 
low. The same limitation can be applied to the operational 
classification: high prevalence regions have mainly PB, while 
in low prevalence areas, the MB forms are more frequently 
identified15.
The later diagnosis and greater proportion of MB cases 
in areas with lower prevalence can also be explained by 
immunological factors. Approximately 80% of the population 
is potentially resistant to leprosy and able to develop cell-
mediated immunity against the bacillus12. However, such 
capacity is not present at birth but is developed over the years 
when the infection occurs early. It is therefore common, in 
endemic areas, to acquire cellular immunity, which occurs at 
the expense of PB infection. The younger the individual has 
contact with the disease, the greater the likelihood of developing 
the PB form, which explains the higher proportion of PB-
affected young people in endemic areas12,14. As the number 
of potentially contagious patients in hyperendemic areas is 
greater, the probability of an individual receiving a sufficiently 
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FIGURE 1 – (A) Annual detection rate of new cases of leprosy in RS 
1981-2011, with linear trend line. (B) Annual detection percentage of MB 
cases in RS 1990-2011, with linear trend line. (C) Annual percentage of 
diagnosis according to the disability grade 2 (2001-2011), with linear trend 
line. MB: multibacillary.
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high bacterial load able to cause an infection before adulthood 
is greater in those regions. Consequently, PB forms will often 
be more commonly diagnosed in these areas. However, in low 
endemicity areas, individuals are less often exposed to the 
bacillus, so infection occurs later and thus the proportion of MB 
cases is higher12,14. This phenomenon is even more relevant in 
the current context where populations are aging and, therefore, 
may demonstrate impaired immunological responses. Studies 
have shown that among aged populations, there is also a greater 
risk of developing leprosy reactions15, which constitutes the 
primary cause of physical disabilities in patients with leprosy. 
Therefore, even in sites with low endemicity, the occurrence 
of leprosy would have potential socio-economic consequences 
not only to the individual, but also to families and communities. 
Issues such as leprosy reaction episodes and physical disabilities 
may be temporary or become permanent, including restriction of 
productive activities, which can even occur after completion of 
treatment. Nevertheless, the manner in which leprosy behaves in 
response to changes in immunity among older patients must be 
better evaluated because, in areas such as RS, patterns of leprosy 
are characterized by aged MB patients10,12. Observing these 
specific profiles among populations from other regions might 
generate insights to promote specific strategies of prevention 
and improvement in heath among these populations.
In conclusion, it can be confirmed that RS remains a low 
endemicity area for leprosy with the disease virtually eliminated. 
This is exhibited by low detection rates among patients younger 
than 15 years of age (lower than were recorded in the 1980s) 
and preponderance of MB cases (according to WHO operational 
classification) with an upwards trend. However, it is impossible 
to determine the true prevalence of leprosy using only these 
indicators because many cases are still underreported or 
diagnosed late. Considering this, WHO also recommends that 
the degree of disability at diagnosis is used as an epidemiological 
indicator to estimate the delay in diagnosis12. Thus, there is 
a growing trend in the diagnosis of cases with a degree of 
disability equal to 2 (Figure 1C), which allows inference that 
the case has been diagnosed late. 
Despite the extremely high detection rates and high 
prevalence of leprosy in most of Brazil, RS has achieved the 
goal of eliminating the disease (<1.00/10,000 inhabitants) by 
reaching a prevalence of 0.16/10,000 in 20098. However, care 
must be taken in the interpretation of this data because the 
diagnosis may be occurring late, which increases the potential 
for transmission. Furthermore, it should be noted that the more 
prevalent MB form predisposes to increased reactional cases, 
especially erythema nodosum leprosum (one of the main causes 
of disability and the most observed reaction in this form of the 
disease)13.
Finally, although leprosy is now considered to be eliminated 
from RS, the data presented highlight the need for intensified 
control activities, such as searching for active disease with 
available rapid tests for contacts to improve early diagnosis to 
avoid reaction outbreaks and subsequent disabilities. 
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